Change in (18)F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment

BACKGROUND: Bevacizumab (BEV), a humanized monoclonal antibody, become a currently important chemotherapeutic option for the patients with recurrent glioma. The aim of this retrospective study is to investigate whether (18)F-Fluoromisonidazole (FMISO) PET have the potential to detect BEV-resistant g...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Yamaguchi, Shigeru, Hirata, Kenji, Toyonaga, Takuya, Kobayashi, Kentaro, Ishi, Yukitomo, Motegi, Hiroaki, Kobayashi, Hiroyuki, Shiga, Tohru, Tamaki, Nagara, Terasaka, Shunsuke, Houkin, Kiyohiro
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5148016/
https://ncbi.nlm.nih.gov/pubmed/27936194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0167917
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados